Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
The publication, entitled, “High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders,” showed that OLC had the lowest daily phosphate binder dose volume and the lowest volume required to bind 1 g of phosphate compared to five other commercially available phosphate binders.
- The publication, entitled, “High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders,” showed that OLC had the lowest daily phosphate binder dose volume and the lowest volume required to bind 1 g of phosphate compared to five other commercially available phosphate binders.
- “A key focus for management of CKD is phosphate control, but currently available binders have suboptimal phosphate-binding capacity, and their characteristics often result in low adherence and suboptimal phosphate regulation.
- Patients often find it difficult to adhere to their phosphate binder prescription due to issues of high pill burden, poor palatability, and side-effects.
- The results of the study showed that the daily phosphate binder dose volume was lowest with oxylanthanum carbonate (OLC) (2.3 cm3) and highest with sevelamer carbonate (9.7 cm3).